Merc's Strong Earnings Driven by New Tumor Drugs and Revitalized Life Sciences

about 1 month ago

Chloe Malay

"Meanwhile the pharmaceutical company Merc is, yeah, driving some conversations. Why? So yeah, the German science conglomerate reported better than expected profit this morning. So that was thanks to strong sales of its new tumor drugs, but then also really strong performance in some parts of its life science unit, which is the biggest division for Merc. So the parts that did particularly well are the ones that provide the equipment to manufacture drugs and that is a part of that business that had seen a little bit of a slowdown post pandemic because of detocking, but now it's reacelerating again."

The discussion highlights Merc's better-than-expected earnings fueled by robust sales of new tumor drugs and a rebound in its life sciences division. The commentary notes improvements in manufacturing equipment sales that had previously slowed post-pandemic.

Related Stocks